Completed PHASE2 INTERVENTIONAL 2-arm NCT00210314

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Conditions Lymphoma, B Cell

Interventions high dose cytarabine high dose methotrexate radiotherapy

Updated 7 times since 2017 Last updated: Mar 27, 2015 Started: Jul 31, 2003 Primary completion: Sep 30, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00210314, this PHASE2 trial focuses on Lymphoma, B Cell and remains completed. Sponsored by International Extranodal Lymphoma Study Group (IELSG), it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

International Extranodal Lymphoma Study Group (IELSG)

Data source: International Extranodal Lymphoma Study Group (IELSG)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bellinzona, Switzerland